Skip to main navigation

Menu

Skip to content

Investors

Alnylam

E-mail Alerts

Download Center

Print

Share this on:
Delicious
Digg
Facebook
LinkedIn
Twitter

Financial Information

FinancialMenu

Fundamentals
Financial Information
Quarterly Results
Key Ratios
Annual Reports

Here you will find a summary of Alnylam Pharmaceuticals, Inc.'s latest financial information.

Show all

Latest Earnings Release and 10-Q

Second Quarter Financial Results
Form 10-Q

Show all

Latest Annual Report and 10-K

2016 Annual Report
Form 10-K

Show all

Latest Proxy Statement

Latest Proxy Statement

Share Related Items

Market Capitalization (Mil)	$7,716.06
Shares Outstanding (Mil)	$100.67
Shares Outstanding, Average (FY) (Mil)	$90.55
Float (Mil)	$89.18

Copyright Thomson Reuters Corporation

FY = Fiscal Year. MRQ = Most Recent Quarter. mil = Millions. TTM = Trailing Twelve Months.

Search

Recent Press Releases

View all releases

Oct 15,2018

Summary Toggle Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran
Oct 10,2018

Summary Toggle Alnylam Appoints Dr. Margaret Hamburg to Board of Directors
Oct 04,2018

Summary Toggle Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1

View all releases

: (Common):

Price:
Change (%):
Volume:
Data as of Copyright NASDAQ. Minimum 15 minutes delay

twitter
linkedin
youtube
rss

Copyright © 2018 Alnylam Pharmaceuticals, Inc. --- All Rights Reserved --- Glossary | Media Kit | Legal | Privacy Policy | Site Map